Moderna to supply Africa with up to 110 million doses at 'lowest tiered price'
Moderna announced Tuesday that it will make up to 110 million doses of its COVID-19 vaccine available to African nations at the company's "lowest tiered price."
The Massachusetts-based biotechnology firm said it is prepared to deliver the first 15 million doses by the end of this year, with 35 million doses in the first quarter of 2022 and up to 60 million doses in the second quarter.
"All doses are offered at Moderna’s lowest tiered price," the company said in a press release Tuesday.
Africa, the world's second-largest and second-most populous continent, remains the least-vaccinated region of the world against COVID-19, with just over 5% of its 1.3 billion people fully inoculated.
Moderna CEO Stephane Bancel said the new agreement with the African Union, a continental bloc consisting of the 55 member states that make up the countries of Africa, was facilitated in part by the White House. The deal is separate from the company's agreement with the global vaccine-sharing initiative COVAX to supply up to 500 million doses from late this year through 2022, according to the press release.
"This is the first step in our long-term partnership with the African Union," Bancel said in a statement Tuesday. "We believe our vaccine can play an important role in addressing the needs of low-income countries given its combination of high Phase 3 efficacy against COVID-19, strong durability in the real-world evidence, and superior storage and handling conditions. We recognize that access to COVID-19 vaccines continues to be a challenge in many parts of the world and we remain committed to helping to protect as many people as possible around the globe."
Moderna is also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, in parallel to building an mRNA vaccine manufacturing facility on the continent with the goal of producing up to 500 million doses each year, according to the press release.